Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Molecular Pharmaceutics|July 28, 2021
PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse ModelsThomas Wilson, Giacomo Pirovano, Gu Xiao, et al.
Nature Communications|February 19, 2025
Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylationJuan Liu, Yiyun Shen, Jie Liu, et al.
Cancer Research|November 29, 2019
Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast CancerGu Xiao, Devon Lundine, George K Annor, et al.
Frontiers in Oncology|August 22, 2022
Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 statusRati Lama, Chao Xu, Samuel L Galster, et al.
Biorxiv : the Preprint Server for Biology|April 3, 2026
Mutant p53 Directs PARP to Regulate Replication Stress and Drive Breast Cancer MetastasisGu Xiao, George K Annor, Katherine W Harmon, et al.
Genes & Development|June 18, 2015
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cellsNeil T Pfister, Vitalay Fomin, Kausik Regunath, et al.
Cell|January 24, 2012
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathwayWilliam A Freed-Pastor, Hideaki Mizuno, Xi Zhao, et al.
Cancer Letters|January 10, 2024
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatmentFlorencia P Madorsky Rowdo, Gu Xiao, Galina F Khramtsova, et al.
Biorxiv : the Preprint Server for Biology|December 11, 2023
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatmentFlorencia P Madorsky Rowdo, Gu Xiao, Galina F Khramtsova, et al.
Pageof 5